GlassScriptPhysician profile
Carole L Moodhe
NPI 1659440170
$2,163.72
in general payments reported to CMS, 2019-2025
12 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2021: $17.66 · 2022: $27.22 · 2023: $146 · 2024: $834 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,011.42 | 2023-2025 | Wegovy, Saxenda |
| Amgen INC. | $335.34 | 2019-2025 | Repatha, Krystexxa |
| Novartis Pharmaceuticals Corporation | $203.16 | 2019-2025 | |
| Abbott Laboratories | $163.94 | 2019 | |
| Pfizer INC. | $127.06 | 2025 | |
| Merck Sharp & Dohme LLC | $109.50 | 2019 | |
| Glaxosmithkline, LLC. | $105.72 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $34.43 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $19.50 | 2025 | |
| Almatica Pharma LLC | $18.16 | 2025 | Loreev Xr |
| Astrazeneca Pharmaceuticals LP | $17.83 | 2025 | Airsupra |
| Horizon Therapeutics Plc | $17.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carole Moodhe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.